Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single‐center retrospective analysis

Spoerl, Silvia; Peter, Robert; Wäscher, Dagmar; Götze, Katharina; Verbeek, Mareike; Peschel, Christian; Krackhardt, Angela M.

doi:10.1111/trf.13883

Cited by 17 publications

(15 citation statements)

References 19 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study demostrated that plerixafor in combination with G-CSF is an effective rescue measurement for poor mobilizers. Plerixafor was well tolerated by patients who were used plerixafor for stem cell mobilization [24].…”

Section: Discussionmentioning

confidence: 98%

Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience

Göker

Çiftçiler

Demiroǧlu

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Background and aim: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been considered the standard of treatment care for patients with multiple myeloma (MM). Insufficient mobilization and harvest of peripheral stem cells can be a major obstacle for performing ASCT. This is resulting in a lacking opportunity of cure in patients with MM. The aim of this study was to evaluate the factors which influence mobilization failure in patients with MM. Materials and methods: This study has been performed in a retrospective manner. Two hundred and thirty-four patients with diagnosed MM who underwent stem cell mobilization after induction chemotherapy at Hacettepe University Hospital between the years of 2003 and 2018 were evaluated. Results: A total of 234 patients were included in this study. The median age was 54 (32-76) years at the time of diagnosis. In 209 of 234 patients (89.3%) first mobilization trial was successful. At univariate analysis, among parameters identifiable before mobilization, male gender (p = 0.03), number of chemotherapy cycle before stem cell mobilization (p < 0.001), second ASCT (p < 0.001) and immunomodulatory treatment before stem cell mobilization (p < 0.001) predicted mobilization failure. At multivariate analysis, number of chemotherapy cycle before stem cell mobilization (p = 0.03), second ASCT (p < 0.001) and immunomodulatory treatment before stem cell mobilization (p = 0.02) retained independent predictive power. Conclusion: Detectable different clinical characteristics of MM patients before initiating mobilization may be predictors of poor mobilization. Therefore, the mobilization protocol should be evaluated on a patient basis. Minimization of exposure to chemotheraputic agents in MM patients, especially immunomodulatory agents, may increase CD34+ cell harvest yields.

show abstract

Section: Discussionmentioning

confidence: 98%

Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience

Göker

Çiftçiler

Demiroǧlu

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

show abstract

“…The possible effect of the infusion of tumor cells on longterm outcomes should be interpreted with caution, as unfavorable outcomes may simply reflect more aggressive disease as well as factors inherent to tumor cell mobilization. It is important to note that it is very likely that some of the patients in our study would probably not have proceeded to autologous transplantation without plerixafor treatment [16][17][18]. In support of our findings, results from a 5-year, long-term, phase III, follow-up study (not restricted to poor mobilizers) showed that the use of G-CSF + P did not have a negative effect on PFS and OS in patients with MM, with more than half of all patients with MM still alive 5 years following transplantation [19].…”

Section: Discussionmentioning

confidence: 99%

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Morris

Chabannon

Masszi

et al. 2019

Bone Marrow Transplant

View full text Add to dashboard Cite

Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.

show abstract

“…In the following article, Spoerl and colleagues used a paired t test to compare the concentrations of circulating CD34+ cells in patients being collected for autologous peripheral blood stem cell transplantation. The patients were judged to be poor mobilizers with granulocyte–colony‐stimulating factor stimulation alone.…”

Section: Examples From the Recent Transfusion Literaturementioning

confidence: 99%

One‐ and two‐sample t tests

Hess

2017

Transfusion

View full text Add to dashboard Cite

Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single‐center retrospective analysis

Abstract: Our data demonstrate that plerixafor is highly effective as rescue measurement after mobilization failure with G-CSF alone and short-term clinical outcome after stem cell transplantation is comparable.

Cited by 17 publications

References 19 publications

Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience

Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

One‐ and two‐sample t tests

Contact Info

Product

Resources

About